Saturday 17 October 2026
Export ALPS’s income statement to Excel — free account
Alps Group Inc.
ALPS Healthcare Biotechnology
Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025. In the quarter to September 2025, EPS fell 609.4% and free cash flow fell 26.5%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow ALPS
| Mar '26 | Mar '25 | Dec '24 | Mar '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 144.15 | — | — | — | — | — | — |
P/S ratio |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
Beneish M-Score |
(1.64) | — | — | — | — | — | — | — | — | — |
P/Operating CF |
(13.76) | (258.37) | — | (42.66) | — | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
EV/Sales |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
(3.21) | (31.47) | — | (17.11) | — | — | — | — | — | — |
EV/FCF |
(3.21) | (31.47) | — | (17.11) | — | — | — | — | — | — |
Quick Ratio |
0.15 | 0.08 | 0.04 | — | 0.02 | 0.11 | 0.11 | 3.52 | 3.52 | — |
Current Ratio |
0.36 | 0.20 | 0.05 | — | 0.05 | 0.37 | 0.37 | 4.46 | 4.46 | — |
Net Debt/EBITDA |
0.00 | 0.00 | 0.15 | 0.00 | 0.07 | 0.06 | 0.06 | 5.99 | 5.99 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.69 | 0.62 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.28 | 0.64 | 2.08 | 0.59 | (1.06) | (3.26) | (3.26) | 2.72 | 2.72 | — |
Capex/Depreciation |
(0.05) | (0.07) | — | (0.24) | — | — | — | — | — | — |
Interest Coverage |
— | — | (9.10) | — | (20.52) | — | 0.00 | — | (2,714.00) | — |
| 92.43% | 42.60% | 10.90% | 0.00% | (23.33%) | (6.24%) | 0.00% | (0.22%) | 0.00% | — | |
| (28.48%) | (46.40%) | (6.01%) | (15.96%) | 1.79% | 0.19% | 0.00% | (0.10%) | (0.20%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
149.88% | 69.42% | 14.42% | 0.00% | (33.29%) | (46.03%) | (46.03%) | (14.97%) | (14.97%) | — |
Average Days of Receivables |
63.68 | 64.68 | — | 0.00 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | — | — | — | — | — | — |
Selling, General and Administrative Expense of Revenue |
72.02% | 71.22% | 0.00% | 80.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.09 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | — | — | — | — | — | — |
Graham Net Nets |
(3.93) | (0.34) | — | (0.98) | — | — | — | — | — | — |
Graham Number |
— | 4.97 | — | 0.00 | — | — | — | — | — | — |
Earnings Yield |
(75.81%) | (2.96%) | — | 0.69% | — | — | — | — | — | — |
Free Cash Flow Yield |
(27.94%) | (3.18%) | — | (5.84%) | — | — | — | — | — | — |
Revenue per Share |
0.03 | 0.02 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.02) | (0.01) | (0.59) | (0.01) | (0.41) | (0.21) | (0.05) | (0.11) | (0.02) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(0.02) | (0.01) | (0.59) | (0.01) | (0.41) | (0.21) | (0.05) | (0.11) | (0.02) | — |
Cash per Share |
0.00 | 0.00 | 0.07 | 0.00 | 0.02 | 0.02 | 0.01 | 0.28 | 0.05 | — |
Shareholders Equity per Share |
(0.02) | (0.01) | (3.10) | 0.00 | (2.11) | (1.18) | 7.62 | (1.08) | 7.60 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(0.02) | (0.01) | (3.10) | 0.00 | (2.11) | (1.18) | 7.62 | (1.08) | 7.60 | — |
Free Cash Flow |
(2.63) | (1.69) | (2.04) | (1.59) | (1.40) | (0.73) | (0.73) | (0.32) | (0.32) | — |
Working Capital |
(3.50) | (6.00) | (6.78) | — | (3.97) | (0.49) | (0.49) | 0.80 | 0.80 | — |
Capital Expenditures |
(0.06) | (0.08) | — | (0.22) | — | — | — | — | — | — |
Net Current Asset Value |
(8.22) | (6.76) | (14.04) | — | (35.93) | (122.46) | (4.68) | (120.07) | (3.34) | — |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
Capex to Sales |
0.01 | 0.02 | — | 0.09 | — | — | — | — | — | — |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.52 | 0.47 | — | 0.00 | — | — | — | — | — | — |
Cash ROIC |
81.49% | 151.68% | 19.55% | 0.00% | 19.52% | 18.39% | (0.64%) | 13.97% | (0.28%) | — |
Accounts Receivable Turnover |
6.72 | 0.00 | — | 0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
9.83 | 10.32 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Inventory Turnover |
6.29 | 0.00 | — | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
38.71 | 56.68 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Days of Inventory on Hand |
54.55 | 98.08 | — | 0.00 | — | — | — | — | — | — |
Average Receivables |
0.72 | — | — | — | — | — | — | — | — | — |
Average Payables |
0.34 | 0.20 | 0.11 | — | 0.16 | 0.16 | — | — | — | — |
Average Inventory |
0.52 | — | — | — | — | — | — | — | — | — |
Average Assets |
7.05 | 5.42 | 16.29 | 14.44 | 73.79 | 118.33 | 118.37 | 117.96 | 58.98 | — |
Average Common Equity |
(2.17) | (5.90) | (8.97) | — | (5.66) | (3.60) | 55.34 | 55.22 | — | — |
Columns are period end dates